Tenax Therapeutics: BlackRock reports 7.5% stake

BlackRock reported sole voting power over 2,754,990 shares and sole dispositive power over 2,804,788; no other person's interest exceeds 5%.

Rhea-AI Filing Summary

TENAX THERAPEUTICS, INC. (TENX), the issuer, is the subject of BlackRock, Inc.’s report of beneficial ownership of 2,804,788 common shares, or 7.5% of the class, as of September 30, 2026. BlackRock reported sole voting power over 2,754,990 shares and sole dispositive power over 2,804,788 shares, with no shared voting or dispositive power.

The reported amount reflects certain BlackRock business units and subsidiaries and affiliates, excluding securities, if any, held by business units disaggregated from those reporting units. BlackRock stated that various persons may receive dividends or proceeds from sales, but no one person’s interest is more than 5% of TENAX’s outstanding common shares.

Key Figures

Beneficial ownership: 2,804,788 shares Percent of class: 7.5% Sole voting power: 2,754,990 shares +3 more

6 metrics

Beneficial ownership 2,804,788 shares As of September 30, 2026

Percent of class 7.5% Beneficial ownership as of September 30, 2026

Sole voting power 2,754,990 shares As reported

Sole dispositive power 2,804,788 shares As reported

Shared voting power 0 shares As reported

Shared dispositive power 0 shares As reported

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Shared Voting Power

4 terms

beneficially owned regulatory

"Amount beneficially owned: 2804788"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power regulatory

"Sole Voting Power 2,754,990.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"Sole Dispositive Power 2,804,788.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Shared Voting Power regulatory

"Shared Voting Power 0.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TENX shares does BlackRock report beneficially owning?

BlackRock, Inc. reported beneficial ownership of 2,804,788 TENAX common shares, or 7.5% of the class, as of September 30, 2026. The reported amount reflects certain BlackRock business units and affiliates and excludes securities, if any, held by business units disaggregated from those reporting units.

How many TENX shares can BlackRock vote or dispose of?

BlackRock reported sole voting power over 2,754,990 shares and sole dispositive power over 2,804,788 shares, with zero shared voting and dispositive power. It also stated that no one person’s interest in TENAX common stock is more than 5% of the outstanding common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 05:28 PM EDT Accepted by SEC EDGAR 10/27/2026 - 05:25 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

TENAX THERAPEUTICS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

88032L605

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,754,990.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,804,788.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,804,788.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TENAX THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 101 Glen Lennox Drive, Suite 300 Chapel Hill NC 27517
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 88032L605
Item 4.	Ownership
(a)	Amount beneficially owned: 2804788
(b)	Percent of class: 7.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2754990
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2804788
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of TENAX THERAPEUTICS INC. No one person's interest in the common stock of TENAX THERAPEUTICS INC is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	10/27/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7